Covered recipient · General Payments record
MICHAEL WILLIAM VAVRA
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
General Payments · PY2018–2024
$5,755.06
- Reported across 333 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,689.38 | 72 |
| Education | $16.72 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| MDD US Operations, LLC | $223.45 | 1 |
| ABBVIE INC. | $209.85 | 14 |
| EMD Serono, Inc. | $135.04 | 7 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $85.31 | 4 |
| Lundbeck LLC | $84.52 | 3 |
| ARGENX US, INC. | $81.40 | 3 |
| Amgen Inc. | $71.85 | 3 |
| BANNER LIFE SCIENCES, LLC | $67.90 | 3 |
| SK Life Science, Inc. | $65.72 | 3 |
| UCB, Inc. | $63.73 | 3 |
| ACADIA Pharmaceuticals Inc | $51.62 | 3 |
| EISAI INC. | $49.39 | 2 |
| Genentech USA, Inc. | $44.24 | 2 |
| Alexion Pharmaceuticals, Inc. | $40.45 | 2 |
| Biogen, Inc. | $39.96 | 2 |
| Vanda Pharmaceuticals Inc. | $39.95 | 1 |
| Celgene Corporation | $35.89 | 2 |
| Abbott Laboratories | $34.06 | 2 |
| ANI Pharmaceuticals, Inc. | $31.75 | 1 |
| Neurelis, Inc. | $30.31 | 1 |
| BOSTON SCIENTIFIC CORPORATION | $29.77 | 1 |
| Xeris Pharmaceuticals, Inc. | $23.39 | 1 |
| Ipsen Biopharmaceuticals, Inc | $21.03 | 1 |
| Neurocrine BioSciences, Inc. | $21.01 | 1 |
| HOSPIRA, INC. | $20.78 | 1 |
| Teva Pharmaceuticals USA, Inc. | $19.68 | 1 |
| GE HEALTHCARE | $18.27 | 1 |
| Acerta Pharma LLC | $18.10 | 1 |
| CATALYST PHARMACEUTICALS, INC. | $16.72 | 1 |
| Azurity Pharmaceuticals, Inc. | $16.68 | 1 |
| Lilly USA, LLC | $14.28 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (73)
Sorted by paying entity, then date · as published by CMS
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.